Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
Welf Prager,1 Eva K Bee,2 Isabel Havermann,1 Ina Zschocke3 1Dermatologikum Hamburg, Hamburg, Germany; 2Praxis für Dermatologie, Hautarztpraxis Stengel and Bee, Münster, Germany; 3SCIderm, Hamburg, Germany Background: IncobotulinumtoxinA (Bocouture®) is free from complexing...
Guardado en:
Autores principales: | Prager W, Bee EK, Havermann I, Zschocke I |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/932974b03b53414ebb1a1743670cf9a7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
por: Prager W
Publicado: (2013) -
Intraoral alveolar submucosal injections of Incobotulinumtoxin A: Relief of therapy-refractory trigeminal neuropathy after tooth extraction
por: Lars Wojtecki, et al.
Publicado: (2021) -
Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines
por: Stengel G, et al.
Publicado: (2011) -
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park J, et al.
Publicado: (2011) -
Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
por: Santamato A
Publicado: (2016)